Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer
Francesco Facchinetti, Ludovic Lacroix, Laura Mezquita, Jean‐Yves Scoazec, Yohann Loriot, Lambros Tselikas, Anas Gazzah, Étienne Rouleau, Julien Adam, Stefan Michiels, Christophe Massard, Fabrice André, Ken A. Olaussen, Gilles Vassal, Karen Howarth, Benjamin Besse, Jean‐Charles Soria, Luc Friboulet, David Planchard
Topics & Concepts
TrametinibDabrafenibVemurafenibKRASMEK inhibitorCancer researchNeuroblastoma RAS viral oncogene homologMedicineV600ELung cancerCrizotinibSanger sequencingPTENMelanomaCancerMutationOncologyBiologyInternal medicineMAPK/ERK pathwayKinaseColorectal cancerGeneticsPI3K/AKT/mTOR pathwayGeneMetastatic melanomaMalignant pleural effusionApoptosisMelanoma and MAPK PathwaysLung Cancer Treatments and MutationsFibroblast Growth Factor Research